Sales & Marketing

Company to discuss acquisition and expansion of executive leadership.

Collaboration to focus on biologics of Kurma’s portfolio companies.

Investigational therapy indicated for the treatment of systemic sclerosis.

New company to be publicly listed as Citius Oncology, Inc.

Deal includes rights to novel antibody for the treatment of inflammatory bowel disease.

Penbraya indicated as the first and only vaccine for the prevention of the five most common serogroups in adolescents.

Companies to jointly develop candidates with potential commercialization agreements included.

Joint venture combines GE’s background in ultrasound technology with Novo Nordisk’s experience with metabolic diseases.

LP-310 designated as an oral formulation of company’s LP-10 asset.

Transaction valued at approximately $3.1 billion.

Agreement includes option for PTC Therapeutics to sell up to all its retained royalties.

Extra capital brings overall funding to $59.5 million.

Initiative started as a response to climate change, company says.

Qlosi indicated for adult patients.

Etrasimod indicated for adult patients with moderate-to-severe diagnosis.

Drug supplier receives $3.45 billion in commitment in new financing.

Treatment indicated for patients with BRAF V600E-mutant metastatic form of disease.

Treatment previously received emergency use authorization by the FDA.

KYV-101 designed as a CD19 CAR T-cell therapy.

Site aims to advance regenerative medicines on a global scale.

Cosentyx is the first intravenous formulation interleukin-17A antagonist to focus on disease.

Developed by Bio-Thera Solutions, treatment is indicated for patients with three different types of arthritis.

Acquisition includes company’s inflammatory disease medicines.

Addition strengthens neuroscience pipeline, company says.

Lofaso discusses strategies that biotech companies can take once its time to make the big push.

Transaction made with intent to develop new drugs, company says.

Company expects treatment to be available across the country.

Separate entity allows company to concentrate on status as focused medicines company.

Collaboration to focus on ulcerative colitis and Crohn’s disease.

Joint venture aims to enable early detection of eye diseases and prevent vision loss.